<?xml version="1.0" encoding="UTF-8"?>
<p>All serum specimens were tested by DENV serotype-specific, real-time, reverse transcriptase polymerase chain reaction (RT-PCR) 
 <xref rid="pntd.0001614-Chien1" ref-type="bibr">[12]</xref>, 
 <xref rid="pntd.0001614-Johnson1" ref-type="bibr">[13]</xref>. Specimens were also tested for anti-DENV IgM with an IgM antibody-capture enzyme-linked immunosorbent assay (MAC-ELISA) 
 <xref rid="pntd.0001614-Miagostovich1" ref-type="bibr">[14]</xref>. Specimens with borderline results were retested against a standard negative serum. A quantitative IgG ELISA was performed to detect anti-DENV IgG in all specimens 
 <xref rid="pntd.0001614-Johnson2" ref-type="bibr">[15]</xref>. As human West Nile virus (WNV) infections were identified for the first time in Puerto Rico in early 2007 (i.e., among healthy blood donors), 
 <xref rid="pntd.0001614-Hunsperger1" ref-type="bibr">[16]</xref> all fatal cases were tested by anti-WNV MAC-ELISA and if positive, WNV specific RT-PCR 
 <xref rid="pntd.0001614-Martin1" ref-type="bibr">[17]</xref> and plaque reduction neutralization test (PRNT90) assays were performed to differentiate between DENV and WNV infections 
 <xref rid="pntd.0001614-Lanciotti1" ref-type="bibr">[18]</xref>.
</p>
